

## HR 5850

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

**Congress:** 118 (2023–2025, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 29, 2023

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 6, 2023)

**Official Text:** <https://www.congress.gov/bill/118th-congress/house-bill/5850>

### Sponsor

**Name:** Rep. Mann, Tracey [R-KS-1]

**Party:** Republican • **State:** KS • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moolenaar, John R. [R-MI-2]	R · MI		Sep 29, 2023

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 6, 2023

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

No related bills are listed.

### Summary

No summary is currently available for this bill.

### Actions Timeline

- **Oct 6, 2023:** Referred to the Subcommittee on Health.
- **Sep 29, 2023:** Introduced in House
- **Sep 29, 2023:** Referred to the House Committee on Energy and Commerce.